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Abstract
Purpose BMS-986142 is an oral, small-molecule reversible
inhibitor of Bruton’s tyrosine kinase. The main objectives of
our phase I studies were to characterize the safety and tolera-
bility, pharmacokinetics, and pharmacodynamics of BMS-
986142 in healthy participants, and to investigate the potential
for the effect of BMS-986142 on the PK of methotrexate
(MTX) in combination.
Methods In a combined single ascending dose and multiple
ascending dose study, the safety, pharmacokinetics, and phar-
macodynamics of BMS-986142 were assessed in healthy non-
Japanese participants following administration of a single
dose (5–900 mg) or multiple doses (25–350 mg, once daily
for 14 days). In a drug–drug interaction study, the effect of
BMS-986142 (350 mg, once daily for 5 days) on the single-
dose pharmacokinetics of MTX (7.5 mg) was assessed in
healthy participants.
Results BMS-986142 was generally well tolerated, alone and
in combination with MTX. BMS-986142 was rapidly
absorbed with peak concentrations occurring within 2 h, and
was eliminated with a mean half-life ranging from 7 to 11 h.
Exposure of BMS-986142 appeared dose proportional within
the dose ranges tested. A dose- and concentration-dependent
inhibition of CD69 expression was observed following
administration of BMS-986142. BMS-986142 did not affect
the pharmacokinetics of MTX.
Conclusions BMS-986142 was well tolerated at the doses
tested, had pharmacokinetic and pharmacodynamic profiles
which support once-daily dosing, and can be coadministered
with MTX without the pharmacokinetic interaction of BMS-
986142 on MTX.
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Introduction
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune
disease affecting 0.5–1.0% of the population in industrialized
countries [1]. Synovial inflammation leads to articular pain,
swelling, and structural destruction that contribute to reduced
quality of life [2]. Treatment includes monotherapy or combi-
nation therapy with classical disease-modifying anti-rheumat-
ic drugs (DMARDs) and biologic agents, including tumor
necrosis factor alpha (TNFα) blockers, anti-cytokine thera-
pies, B cell depleting agents, and costimulation molecule
modulation agents [3–7]. Currently, methotrexate (MTX) re-
mains the cornerstone of RA treatment [6, 7]. Despite recent
progress in RA therapy, some patients either do not reach the
treatment targets of low disease activity or remission, or ex-
perience drug toxicities, or both [8]. Given the complexity,
chronicity, and progressive nature of RA, new safe and effi-
cacious therapies with novel mechanisms of action that com-
plement existing treatments are needed.
Bruton’s tyrosine kinase (BTK) is a member of the Tec
family of nonreceptor tyrosine kinases and is expressed in
all hematopoietic cells except T cells and terminally
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differentiated plasma cells. BTK inhibition is expected to im-
pact mechanisms involving B cell- and non B cell-mediated
autoimmunity such as RA and lupus via B cell receptor, Fc
receptor, and RANK receptor signaling [9–12].
BMS-986142 is an oral, small-molecule reversible inhibi-
tor of the kinase activity of BTK that, unlike rituximab—a B
cell-depleting, anti-CD20 antibody [13]—is expected to in-
hibit antigen-dependent B cell signaling without depleting B
cells. Added benefit against disease endpoints in the
collagen-induced arthritis model was evident when BMS-
986142was combinedwith other agents representing the stan-
dard of care (e.g., MTX), suggesting BMS-986142 may be an
effective therapy for RA. Overall, it appears that BTK is an
attractive novel therapeutic target for RA and other autoim-
mune diseases.
Two phase I studies were conducted to characterize the
safety and pharmacokinetic (PK)/pharmacodynamic (PD)
profile of BMS-986142 in healthy participants, and its
drug–drug interaction (DDI) potential (reported only for
MTX), in order to inform future clinical development.
Overall study design is described in BMethods.^ The fo-
cus of this report is to evaluate the safety, tolerability, PK,
and PD of BMS-986142 after single ascending dose
(SAD) and multiple ascending dose (MAD) administra-
tion in healthy participants in study 1, and to evaluate
the effect of BMS-986142 on the single-dose PK of
MTX (the standard of care in RA patients) in healthy
participants in study 2. The reason for prioritizing this
data was the following: the SAD/MAD data provides a
critical evaluation of the PK, PD and safety profile of
the BTK inhibitor. Secondly, the MTX-DDI results are
relevant to disclose considering the target population.
The remaining portion of studies 1 and 2 will be present-
ed separately from this report.
Methods
Overall study design of two phase I studies
Study 1 was a first-in-human study including SAD and MAD
in non-Japanese participants, MAD in Japanese participants,
and relative bioavailability with food effect in non-Japanese
participants. Study 2 was a DDI study evaluating the effect of
BMS-986142 on the PK of MTX and cocktail probes for
multiple metabolic enzymes and transporters. Herein, we pres-
ent the detailed study design for the portion of SAD andMAD
in Study 1, a phase I, randomized, double-blind, placebo-
controlled study in healthy participants (NCT02257151; data
on file), and for the portion of MTX-DDI in study 2, a phase I,
open-label, single-sequence DDI study in healthy participants
(NCT02456844; data on file). Below, we present the detailed
methods presented in this report.
Study design of SAD and MAD in study 1
Eligible participants were confined to the clinical facility
(WCCT Global, LLC, Cypress, CA) the day before dosing
(day −1) and randomized to receive SAD or MAD treatment
under fasting conditions for 10 h. In the SAD group, eight
healthy non-Japanese participants were assigned to each of
up to six sequential dose panels (single oral doses of 5, 15,
50, 100, 300, and 900 mg BMS-986142) or placebo. Within
each dose panel, participants were randomized in a 3:1 ratio to
receive BMS-986142 (n = 6) or placebo (n = 2). In the MAD
group, eight healthy non-Japanese participants were assigned
to each of four sequential dose panels (daily oral doses of 25,
75, 200, and 350 mg BMS-986142) or placebo. Within each
dose panel, participants were randomized in a 3:1 ratio to
receive once-daily (QD) doses of BMS-986142 or placebo
from day 1 to day 14 (Online Resource 1). Escalation to the
next dose level in SAD and MAD was conducted after safety
assessment had been completed and the treatment was consid-
ered safe and well tolerated. Additionally, dose levels inMAD
were selected not to exceed the steady-state exposure of BMS-
986142 (AUC: 22,920 ng h/mL) at NOAEL in rats obtained
from a 1-month GLP toxicology study.
Eligible participants were healthy males or females (not of
childbearing potential) ages ≥18 to ≤55 years, with a body
mass index of ≥18.0 to ≤32.0 kg/m2, whose health status
was determined by medical history, surgical history, physical
examination, vital signs, electrocardiograms (ECGs), chest X-
ray, and clinical laboratory assessments. Exclusion criteria
included administration or plans for administration of live
vaccine to participants or their household contacts 12 weeks
before or 30 days after the last dose of the study drug; treat-
ment for active tuberculosis within the previous 3 years; his-
tory of herpes zoster; acute or chronic bacterial infection; up-
per respiratory infection; known or suspected infection with
human immunodeficiency virus-1 or virus-2, or hepatitis B or
C viruses; suspected autoimmune disorder; abnormal routine
clinical laboratory values, thyroid function test, or electro-
lytes; and chronic use of steroids.
Study design of MTX-DDI in study 2
This portion of the study was designed to assess the effect of
BMS-986142 on the PK of MTX since MTX is used as a
background therapy in RA patients and all patients will re-
ceive MTX when the phase 2 study of BMS-986142 is con-
ducted. Eligible participants were confined to the clinical fa-
cility for the duration of treatment (15 days). Healthy partici-
pants were administered a single oral dose of 7.5 mgMTX on
day 1. On day 2, participants received leucovorin (a single oral
dose of 15 mg) as a preventive measure for MTX toxicity.
After a washout period (days 2–5), BMS-986142 was admin-
istered on days 6–10 in 350-mg QD doses. A concomitant
Eur J Clin Pharmacol
dose of MTX (7.5 mg) was administered on day 8, followed
by leucovorin (15 mg) on day 9 (Online Resource 2). BMS-
986142 was administered with 240 mL of water, and a mini-
mum amount of additional water was permitted to allow dos-
ing of all medications. Only healthy male participants (ages
≥18 to ≤50 years) were eligible for the MTX-DDI assessment
in study 2. Other key inclusion and exclusion criteria were
identical to those in study 1.
Safety analyses
Participants were monitored for adverse events (AEs)
throughout the study. Clinical laboratory tests, vital sign mea-
surements, 12-lead ECGs, and physical examinations were
performed at selected times throughout the dosing interval.
Safety data was recorded in the participants’ medical records,
and assessments were performed for emergent AEs or serious
AEs (SAEs). For all AEs, causal relationship to the study drug
was determined by an investigator. QT signals obtained from
12-lead ECGs were corrected by heart rate using Fridericia’s
formula (QTcF). Baseline-corrected QTcF (ΔQTcF) were
evaluated to determine QT elongation.
Pharmacokinetic assessments
Blood samples for the measurement of BMS-986142 were col-
lected up to 168 h after dosing of BMS-986142 on day 1 for
participants in SAD. InMAD, blood samples were collected up
to 24 h on day 1 and up to 120 h on day 14 (the last day of
treatment). Blood samples for the measurement of MTX were
collected up to 48 h after dosing of MTX on days 1 and 8.
Plasma samples were analyzed for BMS-986142 levels
with a validated method using liquid chromatography tandem
mass spectrometry (LC-MS/MS) detection. The analyte was
extracted from 50 μL of plasma using a liquid–liquid extrac-
tionmethod.Methyl tert-butyl ether was used as the extraction
solvent. The lower limit of quantification (LLOQ) was
1.00 ng/mL in plasma. Plasma samples were analyzed for
methotrexate levels using LC-MS/MS detection. Analytes
were isolated from 50 μL plasma through solid phase extrac-
tion using Waters Oasis MAX, 10-mg, 96-well SPE plates.
The final extract was analyzed using LC-MS/MS detection.
LLOQ was 1.00 ng/mL in plasma. Detailed methodology
quantitating the concentration level of BMS-986142 and
MTX is provided in Online Resource 10.
Individual subject pharmacokinetic parameters for BMS-
986142 and MTX were derived by a non-compartmental
method using validated PK software (WinNonLin version
6.3; Pharsight Corporation, Mountain View, CA, USA). The
following PK parameters for BMS-986142 and MTX were
derived from plasma concentration versus time data: maxi-
mum observed plasma concentration (Cmax); minimum ob-
served plasma concentration (Cmin); time to maximum
observed plasma concentration (Tmax); area under the plasma
concentration-time curve from time zero to the time of the last
quantifiable concentration (AUC(0-T)), from time zero extrap-
olated to infinite time (AUC(inf)), and in one dosing interval
(AUC(TAU)); terminal plasma half-life (T1/2); and AUC accu-
mulation index (AI_AUC). AI_AUC was calculated to divide
AUC(TAU) on day 14 by AUC(TAU) on day 1.
Pharmacodynamic assessments
To assess the functional effect of BMS-986142 on a relevant
pathway in the targeted cells, whole blood was stimulated
ex vivo with anti-IgD-dextran to activate signal transduction
through the B cell antigen receptor. B cells, identified by
CD20, were assessed for expression of CD69. Blood was
incubated without addition of anti-IgD-dextran to serve as a
negative control. Samples were incubated for 24 h at 37 °C,
and then fixed and stained for CD20 and CD69. CD69 expres-
sion was quantified by standardized flow cytometry.
Fluorescence intensity was measured and reported in units
of mean equivalents of soluble fluorescein (MESF).
Background CD69 level was measured from samples without
the addition of anti-IgD-dextran and was subtracted from the
stimulated value. The anti-IgD specific CD69 induction was
used for analysis. The result for each sample was expressed as
a percentage inhibition relative to the pre-dose sample.
Statistical methods
All recorded AEs were listed and tabulated by system organ
class, preferred term, and treatment. The number and percent-
age of participants with marked laboratory abnormalities were
summarized.
Summary statistics were tabulated for all PK parameters by
treatment and study days. Geometric mean (Gmean) and co-
efficient of variation (CV) are presented for Cmax, AUC(0-T),
AUC(inf), AI_AUC, Cmin, and AUC(TAU); arithmetic mean and
standard deviation (SD) are presented for T1/2; and median
and range are presented for Tmax. Dose proportionality was
assessed using the previously described power model [14].
Briefly, the simple linear regression was applied to the natural
log of the PK parameters on the natural log of dose using the
following equation (Eq. 1).
E log PK Parameterð ÞjDose½  ¼ αþ β*log Doseð Þ: ð1Þ
A slope (β) equal to 1 would indicate perfect dose propor-
tionality. For each PK parameter (Cmax, AUC(0-T), AUC(TAU),
and AUC(inf)), point estimates and 90% CI of the slopes were
calculated.
CD69 inhibition by BMS-986142 was tabulated by treat-
ment and time, and corresponding changes from baseline were
calculated and summarized. The inhibition of B cell receptor-
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mediated CD69 expression by BMS-986142 was descriptive-
ly summarized by treatment and study days. An exposure-
response analysis was applied to characterize the relationship
between BMS-986142 concentration and CD69 inhibition
using a Bayesian Emax model. The Bayesian Emax model
as described below (Eq. 2) was fit to the matched BMS-
986142 plasma concentration and CD69 percent inhibition
data from SAD and MAD panels, and posterior probabilities
of hitting expected target inhibition was estimated. Bayesian
analysis was selected to support the SAD and MAD study.
Compared to the conventional approach, Bayesian approach
provides flexibility to adjust dose levels and efficiently char-
acterize PK and PD profile during the study process.
INH ¼ E0þ Emax Concentration
Hill
EC50HillþConcentrationHill ð2Þ
where INH = CD69 inhibition response, E0 = response at
placebo, Emax = maximum response, and Hill = steepness
parameter.
Statistical analyses were conducted to assess the effect of
coadministration of BMS-986142 on the PK of MTX. For all
treatment comparisons, a linear mixed-effect model was fitted
to the log-transformed PK parameters Cmax, AUC(0-T), and
AUC(inf). Point estimates and 90% CIs for differences on the
log-scale were exponentiated to obtain estimates for geometric
mean ratios (GMRs) and respective 90% CIs on the original
scale. Sample size determination is based on consideration of
the precision of the estimate of the GMRs of AUCs of MTX
with and without BMS-986142. With 9 evaluable subjects,
there will be an 80% probability that the 90% CI of
AUC(INF) GMR will be within 89.9 to 111.2% of the point
estimate. These precision estimates are based on an assump-
tion that Cmax and AUC(INF) of MTX are log-normally dis-
tributed with intrasubject CVof 14.67 and 10.38%, respective-
ly, as calculated from Namour et al. [15].
SAS® version 9.2 or greater (SAS Institute Inc., Cary, NC)
was used for statistical analyses, tabulations and graphical
presentations. R 3.0.1 or greater was used for the Bayesian
Emax model.
Results
Patient characteristics and disposition
A total of 80 participants were enrolled in study 1: 48 patients
in the SAD group (6 participants in each BMS-986142 dose
group, 12 in the placebo group), and 32 in the MAD group (6
participants in each BMS-986142 group, 8 in the placebo
group). A total of 12 participants were enrolled in study 2, in
which the DDI potential of single 7.5-mg doses ofMTX alone
and in combination with BMS-986142 (350 mg QD) was
evaluated (Online Resource 3).
Safety and tolerability
In the study 1 SADgroup, 22AEswere reported in 8 participants
(22.2%) treated with BMS-986142, and 6 AEs were reported by
2 participants (16.7%) treated with the placebo (Table 1, Online
Resource 4). Two of these AEs were of grade 2 severity (synco-
pe, placebo group; headache, 50-mg BMS-986142 group); all
remaining AEs were of grade 1 severity. No clinical symptoms
were associated with laboratory abnormalities.
Table 1 Overall safety summary

















Subjects with AEs 2 (16.7) 8 (22.2) 4 (50) 8 (33.3) 4 (33.3)
Dizziness 0 1 (2.8) 0 0 2 (16.7)
Headache/tension
headache
1 (8.3) 5 (13.9) 1 (12.5) 1 (4.2) 1 (8.3)
Nausea 0 1 (2.8) 0 0 2 (16.7)
Diarrhea 0 1 (2.8) 0 1 (4.2) 0
Cough 0 1 (2.8) 1 (12.5) 1 (4.2) 0
Upper respiratory tract
infection
0 2 (5.6) 0 1 (4.2) 0
Thermal burns 0 1 (2.8) 0 1 (4.2) 0
MAD multiple ascending dose, SAD single ascending dose
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In the study 1 MAD group, 13 AEs were reported in 8
participants (33.3%) treated with BMS-986142, and 5 AEs
were reported in 4 participants (50%) treated with the placebo
(Table 1, Online Resource 4). One subject who received mul-
tiple doses of BMS-986142 (75 mg, QD) had a grade 3 SAE
of a brief psychotic disorder occurring 26 days after the last
administration of the study drug. This event occurred shortly
after an esophagogastroduodenoscopy procedure that the sub-
ject underwent as a participant of another clinical study. The
event was considered not related to the study drug by the
investigator. One subject had a grade 3 AE of increased blood
creatine phosphokinase that was considered unrelated to the
study drug by the investigator. Two AEs were of grade 2
severity (syncope, placebo group; rash, 350-mg BMS-
986142 group), while all remaining AEs were of grade 1 se-
verity in the MAD group.
Alanine aminotransferase (ALT) elevation was identified
during the study as an event of special interest. Modest eleva-
tion of ALT (<3× upper limit of normal [ULN]) was noted and
the frequency of marked ALT elevation was low. The highest
measured level of ALT was 177 units per liter (U/L) (between
ALT ≥3× and <5× ULN, where ULN = 55 U/L) and occurred
in the placebo group the SAD portion of the study. The same
subject had an AST elevation (72 U/L) that was approximately
1.5× ULN (ULN = 50 U/L). No clinically relevant changes of
QTcF from baseline were observed in SAD and MAD (Online
Resources 5 and 6). No participants showed greater than 30 ms
increase from baseline in the maximum post-dose QTcF.
In study 2, the DDI study with MTX, four participants
experienced 12 AEs of grade 1 severity that did not require
any treatment or dose adjustment. Three AEs were reported in
1 subject who received single-dose MTX on day 1, 2 AEs
were reported in 2 participants who received BMS-986142
administration on days 6 and 7, and 9 AEs were reported in
4 participants who received concomitant MTX and BMS-
986142 (days 8–10). Among reported AEs, the most common
(≥2 episodes) were dizziness, headache, and nausea. Two par-
ticipants experienced AEs related to the study drug. These
Fig. 1 Mean concentration vs.
time profiles of BMS-986142
after a SAD and bMAD
administration. Lower limit of
quantification (LLOQ) = 1.00 ng/
mL. MAD multiple ascending
dose, SAD single ascending dose
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were dizziness and nausea reported in both participants, oc-
curring after administration of MTX with BMS-986142. All
other drug-related AEs after coadministration of MTX with
BMS-986142 were reported in 1 subject each. There were no
drug-related AEs after administration of MTX alone or BMS-
986142 alone (Table 1, Online Resource 7). Overall, BMS-
986142 and MTX were well tolerated when administered
alone or in combination.
Pharmacokinetics
Mean concentration versus time profile after a single-dose
administration is presented in Fig. 1a. Following single-dose
administration of BMS-986142 over the 5–900 mg dose
range, BMS-986142 was rapidly absorbed (median Tmax up
to 2 h). Mean T1/2 ranged 7 to 11 h (Table 2). Increases in Cmax
and AUC(inf) after a single-dose administration appears to be
approximately dose proportional from 5 to 900 mg of BMS-
986142 as the slope of the regression line was close to 1 and
the corresponding confidence interval was entirely contained
within 0.80 to 1.25 (Online Resource 8, Online Resource 9).
Mean concentration versus time profile at steady state fol-
lowing multiple doses is presented in Fig. 1b. After multiple-
dose administration, steady-state PK behavior was consistent
with that following a single-dose administration. (Table 2).
Dose-proportional increases in Cmax and AUC(TAU) at steady
state were observed from 25 to 350 mg as the slope of the
regression line was close to 1 and the corresponding confi-
dence interval included 1 (Online Resource 8, Online
Resource 9). No changes in Tmax and T1/2 were observed in
comparison to the SAD part of the study. The accumulation
index (AI) for AUC indicated a minimal to modest accumu-
lation in MAD.
MTX exposures were comparable when administered
alone or with BMS-986142. The coadministration of BMS-
986142 did not appear to affect the Cmax and AUC(inf) of
MTX as GMRs approximated 1 and the 90% CIs of the ad-
justed GMRs were entirely contained within 0.80 to 1.25
(Table 3). Plasma MTX concentration versus time curves for
Table 2 Pharmacokinetic parameters for BMS-986142 after (a) single-dose administration and (b) at steady state after multiple-dose administration











T1/2 (h) mean (SD)
5 mg, n = 6 9.03 (37) 2.03 (1.00, 4.00) 83.1 (51) 102 (52)a 6.87 (3.35)a
15 mg, n = 6 36.9 (21) 2.00 (1.00, 2.00) 369 (12) 388 (10) 8.02 (1.37)
50 mg, n = 6 185 (38) 1.00 (1.00, 2.05) 1561 (31) 1586 (31) 9.70 (1.65)
100 mg, n = 6 311 (17) 1.50 (1.00, 2.00) 2999 (14) 3019 (14) 10.3 (1.03)
300 mg, n = 6 1081 (25) 1.02 (1.00, 2.00) 11,347 (21) 11,390 (21) 10.6 (1.05)
900 mg, n = 6 1878 (31) 2.00 (1.00, 4.00) 28,026 (32) 28,063 (31) 10.7 (2.01)















25 mg, n = 6 56.0 (25) 2.00 (2.00, 4.00) 7.85 (42) 539 (34) 1.57 (22) 10.9 (1.8)
75 mg, n = 6 281 (34) 2.00 (1.00, 2.00) 27.9 (77) 2471 (44) 1.23 (31) 10.7 (1.6)
200 mg, n = 6 592 (37) 2.00 (1.00, 2.00) 67.6 (63) 5527 (41) 1.23 (40) 11.0 (4.6)
350 mg, n = 6 1024 (14) 1.50 (1.00, 2.00) 166 (41) 10,715 (26) 0.984 (32) 10.2 (0.9)
AI_AUC AUC accumulation index, AUC(0-T) area under the plasma concentration-time curve from time zero to the time of the last quantifiable
concentration, AUC(inf) area under the plasma concentration-time curve from time zero extrapolated to infinite time, AUC(TAU) area under the plasma
concentration-time curve in one dosing interval, Cmax maximum observed plasma concentration, Cmin minimum observed plasma concentration, MAD
multiple ascending dose, SAD single ascending dose, T1/2 terminal plasma half-life, SD standard deviation, Tmax time to maximum observed plasma
concentration
a n = 5
Table 3 Adjusted geometric mean ratios for Cmax and AUC of
methotrexate administered as a single dose and in combination with
BMS-986142
PK parameter Treatment Geometric mean
(adjusted)
90% CI
Cmax (ng/mL) D 178 (154, 205)
F 186 (166, 209)
F vs D 1.046 (0.910, 1.202)
AUC(0-T) (ng h/mL) D 613 (550, 683)
F 638 (568, 717)
F vs D 1.041 (0.950, 1.139)
AUC(inf) (ng h/mL) D 625 (563, 695)
F 654 (583, 733)
F vs D 1.045 (0.954, 1.145)
AUC(0-T) area under the plasma concentration-time curve from time zero
to the time of the last quantifiable concentration, AUC(inf) area under the
plasma concentration-time curve from time zero extrapolated to infinite
time, CI confidence interval, Cmax maximum observed plasma
concentration, PK pharmacokinetic. Treatments: D single-dose
methotrexate 7.5 mg (day 1) + single-dose leucovorin 15 mg (day 2), F
BMS-986142 350 mg QD (days 8 to 10) + single-dose methotrexate
7.5 mg (day 8) + single-dose leucovorin 15 mg (day 9)
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single-dose administration and coadministration with BMS-
986142 were superimposable (Fig. 2).
Pharmacodynamics
Dose- and concentration-dependent inhibition of ex vivo anti-
IgD-dextran induced CD69 expression were observed follow-
ing single- or multiple-dose administration of BMS-986142.
Mean maximal inhibition was close to 100% at dose levels
greater than 100 mg, and sustained inhibition over a dosing
interval was observed at steady state following multiple dos-
ing at the 350-mg dose level (Fig. 3). Based on the relationship
between concentration of BMS-986142 and corresponding
inhibition of CD69 expression, the concentration to inhibit
50% of CD69 expression was 0.145 μM [83 ng/mL]
(Fig. 4). Plasma concentration above 0.145 μM [83 ng/mL]
for the entire duration at steady state was achieved at doses at
or above 350 mg QD.
Discussion
In the current study, BMS-986142 was generally well tolerat-
ed and exhibited a dose- and concentration-dependent inhibi-
tion of CD69 expression. Overall, the PK and PD profiles of
BMS-986142 following single or multiple dosing supported
once-daily dosing for future clinical studies. BMS-986142 did
not affect the PK of MTX, and coadministration of BMS-
986142 and MTX was generally well tolerated.
In healthy persons, B cells, and BTK, are not active. Thus,
measurement of in vivo inhibition is problematic. To work
around this issue, B cell activity was stimulated in vitro and
CD69 expression was evaluated. CD69 expression can be
induced downstream of the B cell receptor; thus, suppression
of CD69 expression reflects inhibition of B cell activation.
Since BTK is required for B cell receptor-mediated activation,
it can serve as a surrogate marker for target (BTK) engage-
ment [16]. BMS-986142 produced a dose- and concentration-
dependent decrease in CD69 expression, indicating an ex vivo
target engagement. Based on PK/PD analysis in SAD and
MAD, the derived IC50 was 0.145 μM. This value was similar
with that derived from in vitro evaluation (0.090 μM) [17]. It
Fig. 2 Plasma methotrexate (MTX) concentration vs. time curves for
single-dose administration and coadministration with BMS-986142. QD
once daily; LLOQ = 1.00 ng/mL
Fig. 3 Change in CD69
expression vs. time after a single
ascending dose (SAD) and b
multiple ascending dose (MAD)
administration
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appears that a 350-mg QD dosing regimen is able to maintain
plasma concentrations above the IC50 of CD69 inhibition
over the entire dosing interval at steady state.
Inhibition of BTK-dependent processes such as B cell
receptor-mediated B cell functions, IgG-containing immune
complex signaling through Fcγ receptors in monocytic cells,
and RANK-dependent osteoclastogenesis is expected to pro-
vide benefit in the treatment of autoimmune disorders such as
RA, where these pathways are involved in disease pathogen-
esis [9, 10]. Dose-dependent efficacy of other BTK inhibitors
such as PCI-32765 and GDC-0834 has been demonstrated in
animal models of arthritis [18, 19]. Further, the BTK inhibitor
RN486, when administered alone or in combination with
MTX, was efficacious in reducing joint and systemic inflam-
mation in a rat adjuvant-induced arthritis model [20]. Using a
collagen-induced arthritis model, newer understanding of
BTK function with inhibitors (CGI1746) for B cell or myeloid
cell-driven diseases is generating compelling evidence and
rationale for targeting BTK in RA [21]. Exploration of BTK
inhibitors to treat RA is ongoing in nonclinical and clinical
studies [22, 23].
There was a single SAE (psychotic event requiring hospi-
talization) reported during the study. The SAE occurred in the
MAD 75-mg group and was considered unrelated to the study
drug. It occurred 26 days after the last dose of the study drug
and approximately 1 day following a gastroscopy procedure
that the subject underwent as a participant of another clinical
study. No dose-limiting AEs or clinically significant laborato-
ry abnormalities were observed. No participants had an ALT
>3× ULN and a total bilirubin >2× ULN on the same date.
There were no apparent trends in vital signs or laboratory
values following single- and multiple-dose administration of
BMS-986142 and no clinically relevant changes in individual
ECG intervals or changes from baseline were noted. There
appeared to be a relationship between change from baseline
in QTcF interval and BMS-986142 plasma concentration fol-
lowing single-dose administration of BMS-986142, but there
was no apparent relationship following multiple dosing of
BMS-986142. Similar trends were noted following model-
based assessment [24]. These results will be explored further
via a formal, thorough QT study.
The observed PK profile of BMS-986142 supports QD
dosing in future clinical studies. Dose-proportional increases
in Cmax and AUCs were demonstrated following single- or
multiple-dose administration, and multiple QD dosing of
BMS-986142 led to modest accumulation at therapeutically
relevant dose levels. Mean T1/2 was up to 11 h at therapeutic
doses. At low dose levels, a shorter T1/2 (∼7 h) was observed.
It is likely that terminal phase may not be fully characterized at
these dose ranges since concentration levels at terminal phase
may be below the LLOQ. Considering the observed T1/2, the
modest accumulation of BMS-986142 was predicted follow-
ing a QD dosing. The observed range of accumulation is con-
sistent with the prediction. However, it should be noted that AI
values appear to decrease with increasing dose levels. There
may be dynamic changes such as the inhibition and/or induc-
tion of metabolic enzymes associated with the elimination of
BMS-986142. These changes may be dose-dependent. These
findings will be explored further in the future studies. It ap-
pears that the increases in Cmax were approximately dose
proportional but showed the wide fluctuation across the dose
range in SAD. Therefore, the dose-proportional increase in
Cmax is not conclusive in SAD. MTX is the standard of care
for treatment of RA; therefore, RA patients commonly receive
it as a background therapy. Hence, confirming whether BMS-
986142 affects the PK of MTX was important before
conducting a clinical study in RA patients. Results from our
current study demonstrated that BMS-986142 did not affect
the PK of MTX, and coadministration with MTX was well
tolerated. These results suggest that BMS-986142 can be ad-
ministered safely to RA patients receiving MTX as a back-
ground therapy without restrictions or dosage adjustments.
Conclusion
In summary, BMS-986142 was well tolerated and also pro-
duced sustained inhibition of CD69 expression. The PK pro-
file of BMS-986142 was linear, supporting once-daily dosing,
and no PK interaction with MTX was observed. Dose- and
concentration-dependent inhibition of CD69 expression,
representing target engagement, was observed. Collectively,
Fig. 4 BMS-986142 plasma concentration and CD69% inhibition
relationship curve. Data included participants with matching
concentration of BMS-986142 and CD69 inhibition. Placebo
participants were excluded from the analysis. Data excluded values of
CD69% inhibition >100 or ≤−100. For illustration purposes, Y-axis
only presented from 0 to 100%. IC50 = BMS-986142 concentration to
inhibit the 50% of CD69 expression
Eur J Clin Pharmacol
these results—combined with reports from other BTK inhib-
itors—support the further development of BMS-986142 for
the treatment of RA and other inflammatory diseases.
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